UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339

2020

Volltextzugriff (PDF)

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung

Journal of clinical oncology, 2017-02, Vol.35 (4), p.412-420

2017

Volltextzugriff (PDF)

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1872-1882

2021

Volltextzugriff (PDF)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Applied immunohistochemistry & molecular morphology, 2019-02, Vol.27 (2), p.92

2019

Volltextzugriff (PDF)

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2040-2050

2021

Volltextzugriff (PDF)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients

PloS one, 2021-02, Vol.16 (2), p.e0246486-e0246486

2021

Volltextzugriff (PDF)

Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS

PloS one, 2012-07, Vol.7 (7), p.e40443-e40443

2012

Volltextzugriff (PDF)

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC

JTO clinical and research reports, 2022-07, Vol.3 (7), p.100341-100341, Article 100341

2022

Volltextzugriff (PDF)

Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse

Development (Cambridge), 1994-06, Vol.120 (6), p.1357-1372

1994

Volltextzugriff (PDF)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Proceedings of the National Academy of Sciences - PNAS, 2018-10, Vol.115 (43), p.E10119-E10126

2018

Volltextzugriff (PDF)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab

PloS one, 2021-02, Vol.16 (2), p.e0246486

2021

Volltextzugriff (PDF)

ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS619-TPS619

2023

Volltextzugriff (PDF)

OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer

Future oncology (London, England), 2024-06, p.1-21

2024

Volltextzugriff (PDF)

Abstract 5707: On-treatment changes in CRP as a surrogate for overall survival for atezolizumab benefit in 2nd line NSCLC

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5707-5707

2018

Volltextzugriff (PDF)

The role of autoantigens in autoimmune disease

Current Opinion in Immunology, 2000-12, Vol.12 (6), p.725-730

2000

Volltextzugriff (PDF)

Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial

Journal of rheumatology, 2003-03, Vol.30 (3), p.449

2003

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9594-9594

2020

Volltextzugriff (PDF)

IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21623-e21623

2020

Volltextzugriff (PDF)

Mouse γδ TCR+NK1.1+ thymocytes specifically produce interleukin‐4, are major histocompatibility complex class I independent, and are developmentally related to αβ TCR+NK1.1+ thymocytes

European journal of immunology, 1996-07, Vol.26 (7), p.1424-1429

1996

Volltextzugriff (PDF)

The cytokine stew and innate resistance to L. monocytogenes

Immunological reviews, 1997-08, Vol.158 (1), p.107-114

1997

Volltextzugriff (PDF)

Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer

Cancer chemotherapy and pharmacology, 2015-02, Vol.75 (2), p.401-410

2015

Volltextzugriff (PDF)

P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients: Topic: IT

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1299-S1300

2017

Volltextzugriff (PDF)

P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1299-S1300

2017

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(48)
Buchkapitel
(1)

Sprache

Englisch
(49)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(17)
Humans
(13)
Animals
(9)
Mice
(8)
Female
(7)
Lung Neoplasms - Drug Therapy
(7)
Biological And Medical Sciences
(6)
Immunology
(6)
Middle Aged
(6)
Oncology
(6)
Aged
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Male
(5)
Monoclonal Antibodies
(5)
Adult
(4)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)
Fundamental And Applied Biological Sciences. Psychology
(4)
Immunohistochemistry
(4)
Immunotherapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients

Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC

Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab

ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery

OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer

Abstract 5707: On-treatment changes in CRP as a surrogate for overall survival for atezolizumab benefit in 2nd line NSCLC

The role of autoantigens in autoimmune disease

Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial

Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC

IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC)

Mouse γδ TCR+NK1.1+ thymocytes specifically produce interleukin‐4, are major histocompatibility complex class I independent, and are developmentally related to αβ TCR+NK1.1+ thymocytes

The cytokine stew and innate resistance to L. monocytogenes

Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer

P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients: Topic: IT

P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients

Suchergebnisse filtern